Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200, a Subcutaneous Glucocorticoid ADC, at EULAR 2026

Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company, presented first-in-human data for LFD-200, a novel subcutaneously administered antibody-drug conjugate (ADC) that delivers a potent glucocorticoid directly to immune cells, at the European Congress of Rheumatology (EULAR) 2026 in London, UK. The Phase 1 study in healthy participants demonstrated that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity. Dosing of patients with moderate to severe rheumatoid arthritis (RA) in the Phase 1 study is ongoing, with data expected by year-end 2026.

The presentation highlighted key takeaways from the initial Phase 1 data, showing that LFD-200 was safe and well tolerated, and demonstrated anti-inflammatory effects without affecting cortisol. This is a significant advancement because systemic glucocorticoids, while effective in treating inflammation, are associated with serious side effects such as adrenal suppression, osteoporosis, and increased infection risk. By targeting the drug directly to immune cells, LFD-200 aims to maximize therapeutic efficacy while minimizing systemic toxicity. The ability to administer the drug subcutaneously also offers convenience over intravenous infusions.

Lifordi is leveraging the success of ADCs, a technology traditionally used in oncology, to develop treatments for autoimmune and inflammatory disorders. LFD-200 is the company's lead ADC, and its favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profile in healthy participants supports further development. The dose-responsive anti-inflammatory activity without cortisol suppression suggests that LFD-200 could provide a safer alternative to conventional glucocorticoid therapies. For more information, Lifordi invites readers to visit www.lifordi.com and follow them on LinkedIn.

The company has also applied its novel drug delivery approach to other payloads, including antisense oligonucleotides (ASOs), siRNA, and small molecules. Backed by investors such as ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is committed to transforming the treatment of immune and inflammatory diseases. The Phase 1 data presented at EULAR 2026 represent an important step toward potentially offering patients a more targeted and safer therapeutic option for rheumatoid arthritis and other inflammatory conditions.